The FDA approved Novo Nordisk’s once-weekly basal insulin Awiqli (insulin icodec) injection for type 2 diabetes, making it the first longer-acting alternative to daily basal insulin in the US. The decision follows a multi-year regulatory path that has already played out across other jurisdictions, positioning Novo Nordisk to compete directly in the basal-insulin franchise.